Clinical research is critical to the advancement of perinatal mental health treatment. Our program has several ongoing clinical research studies aimed at improving treatments for perinatal mood, pain, and opioid use. Below are brief descriptions of ongoing studies and opportunities to participate in clinical research.

Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): A Pragmatic Randomized Trial Comparing Extended-Release and Daily Buprenorphine Formulations

The purpose of this research study is to evaluate the impact of treating Opioid Use Disorder in pregnant women with extended-release buprenorphine, compared to sublingual buprenorphine, on mother and infant outcomes. The study consists of a screening phase, weekly medication visits, and research visits throughout pregnancy and until 12 months postpartum.You may be eligible to join if:

  • You are 18-41 years old
  • You are currently pregnant
  • You have opioid use disorder

For more information and to see if you qualify please contact Savannah Lee at 843-614-9510 or

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of SAGE-217 in the Treatment  of Adults with Severe Postpartum Depression

COM study screen grab 
Skylark Study

The purpose of this study is to  determine if treatment with SAGE-217 reduces depressive symptoms in adult women with severe postpartum depression (PPD) compared to placebo. The study includes a screening period of up to 28 days, a 14-day treatment period, and a follow-up period of up to 34 days. All participants will receive a daily oral dose of SAGE-217 or placebo from Day 1 through Day 14 on an outpatient basis. You may be eligible to join if you:

  • Are 18-45 years old
  • Have Postpartum Depression
  • Are less than 12 months postpartum

For more information and to see if you qualify please contact Natalie Naylon at 843-792-5824 or

Please click on the links below to watch an educational webinar series on Postpartum Depression (PPD).

  • PPD Webinar 1:
    • Overview of PPD
    • Perspectives from a patient, patient advocate, health care provider/physician
    • PPD in the current health care environment; COVID-19
    • Resources and tips to support a loved one with PPD


  • PPD Webinar 2:
    • Perspectives from a patient, health care provider/physician
    • What is a clinical trial and what would it be like to participate?
    • Current & potential future treatments for PPD
    • Impact of COVID-19 on clinical trials and PPD

Pilot RCT of Remote Mental Health and Substance Use Screening, Brief Intervention and Referral to Treatment (SBIRT), Compared to In-Person SBIRT for Peripartum Women

This is a research study to compare a text message based mental health and substance use screening and referral to treatment program, called Listening to Women (LTW), to standard of care mental health and substance use screening. Participation would involve answering questionnaires. 

You may be eligible to join if:

  • You are pregnant or postpartum
  • You are 18-41 years old
  • If you are pregnant, you are receiving prenatal care

For more information and to see if you qualify please contact Tychia Brown at 843-872-2439 or 

Accelerated Theta Burst Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Postpartum Depression 

This study is for those who are currently experiencing postpartum depression. The goal of the study is to see if postpartum women are willing to take part in an accelerated course of rTMS (e.g., 18 treatments over 3 days). You may be eligible to join if you:

  • Are female aged 18 or above
  • Are experiencing depression during pregnancy or following the birth of a child

For more information and to see if you qualify please contact Melanie Wiley at 

Postpartum Depression ACT

PPD ACT is a research app for women who have ever experienced postpartum depression (PPD) or psychosis (PPP). The goal of the study is to improve detection, treatment and prevention of PPD and PPP by finding the genetic basis of these disorders. Women who participate will download the PPD ACT app, fill out questionnaires and if eligible, submit a saliva sample.

You may be eligible to join if you:

  • Are female aged 18 or above
  • Have had a live birth
  • Have an iOS or Android device

For more information, find us on the web at PPD ACT, or find the app in the iTunes or Google Play store by searching “PPD ACT.”

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, & Pharmacokinetics of SAGE-547 Injection in the Treatment of Adult Female Subjects with Severe Postpartum Depression & Adult Female Subjects with Moderate Postpartum Depression*

This is a research study evaluating an investigational medication (SAGE-547, allopregnanolone) in women with moderate to severe postpartum depression. The specific purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of SAGE-547 as a treatment for women with severe or moderate postpartum depression (PPD), an area of high unmet medical need. The study consists of an up to 7-day Screening Period, 3-day inpatient Treatment Period, and 30-day Follow-up Period. Assessments and laboratory samples are collected during the Treatment Period and the Follow-up Period.

*We are no longer enrolling participants in this study. This medication has been approved by the FDA for Postpartum Depression and is being offered as a treatment option in our clinic.